Details

Autor(en) / Beteiligte

• Gatselis, Nikolaos K
• Lygoura, Vasiliki
• Lyberopoulou, Aggeliki
• Giannoulis, George
• Samakidou, Anna
• Vaiou, Antonia
• Vatidis, George
• Antoniou, Katerina
• Stefos, Aggelos
• Georgiadou, Sarah
• Sagris, Dimitrios
• Sveroni, Dafni
• Stergioula, Despoina
• Gabeta, Stella
• Ntaios, George
• Dalekos, George N

Titel

Soluble IL-2R Levels at Baseline Predict the Development of Severe Respiratory Failure and Mortality in COVID-19 Patients

Ist Teil von

• Viruses, 2022-04, Vol.14 (4), p.787

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Risk stratification of coronavirus disease-19 (COVID-19) patients by simple markers is critical to guide treatment. We studied the predictive value of soluble interleukin-2 receptor (sIL-2R) for the early identification of patients at risk of developing severe clinical outcomes. sIL-2R levels were measured in 197 patients (60.9% males; median age 61 years; moderate disease, = 65; severe, = 132, intubated and/or died, = 42). All patients received combined immunotherapies (anakinra ± corticosteroids ± intravenous immunoglobulin ± tocilizumab) according to our local treatment algorithm. The endpoint was the composite event of intubation due to severe respiratory failure (SRF) or mortality. Median (interquartile range) sIL-2R levels were significantly higher in patients with severe disease, compared with those with moderate disease (6 (6.2) vs. 5.2 (3.4) ng/mL, = 0.017). sIL-2R was the strongest laboratory predictive factor for intubation/death (hazard ratio 1.749, 95%CI 1.041-2.939, = 0.035) after adjustment for other known risk factors. Youden's index revealed optimal sIL-2R cut-off for predicting intubation/death at 9 ng/mL (sensitivity: 67%; specificity: 86%; positive and negative predictive value: 57% and 91%, respectively). Delta sIL-2R between the day of event or discharge minus admission date was higher in patients that intubated/died than in those who did not experience an event (2.91 (10.42) vs. 0.44 (2.88) ng/mL; = 0.08)). sIL-2R on admission and its dynamic changes during follow-up may reflect disease severity and predict the development of SRF and mortality.